Immunology

Biography

Biography: Eitan Rubin

Abstract

The move toward precision cancer medicine challenges traditional approaches both in terms of cancer medicine and in terms of clincal trial designs. The WIN consortium was established to promote translational cancer research by facilitating the translation of innovative methodologies to cancer care via collaborative and create clinical trials. The consortium has launched the Winter trial, in which mutations profiling and expression profiling are used to prioritize therapeutic approaches in advanced cancer patients. We are also launching two additional trials, Spring and Summer, which gradually attempt to benefit earlier stages of specific cancers. In this presentation the 3 trials will be briefly described, both in terms of the unique trial designs and in terms of the prioritization principles. I will then show the results we have recently obtained that show that exploring the immune system in situ in the tumor is feasible, and that immune monitoring is useful for predicting treatment efficacy. Altogether we will present exampels of modern, personalized clinical trials and propose that adding immune-monitoring to such trials could strengthen our ability to utilize immunological breakthroughs at the bedside.